Larkspur Biosciences

Larkspur Biosciences is developing the next generation of precision immunotherapies to combat cancer. Despite advances in cancer treatments, many cancer patients still do not respond to existing options. Using LarkX, their proprietary machine learning-enabled gene signature platform, Larkspur’s approach is to target cancer-intrinsic factors that tumors use to escape immune detection. The bioinformatics approach focuses treatment on likely responders so that more targeted trials can be conducted. Larkspur’s lead program is a novel approach to improve antigen-presenting function through lipid remodeling, with other programs in development for colorectal cancer.

Jobs: